The KRAS/ERK/c-Myc axis is the major driver of tumorigenesis in pancreatic cancer; therefore, targeting c-Myc is a promising treatment strategy for PDAC [12, 13]. The gene discussed is MYC; the disease is familial pancreatic carcinoma.